OpenAlex
PricingAboutJobs
Log inGet started
Work

Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study

HTML

Year: 2012
Type: conference-abstract
Source: Cancer Research
DOI: 10.1158/1538-7445.am2012-ct-01
Authors: Dejan Juric, Jordi Rodon, Ana M. Gonzalez-Angulo, Howard A. Burris, Johanna Bendell, Jordan D. Berlin, Mark R. Middleton, Douglas Bootle, Markus Boehm, Antonin Schmitt, Nicolas Rouyrre, Cornelia Quadt, Jose Baselga
Institutions: Massachusetts General Hospital, Vall d'Hebron Hospital Universitari, The University of Texas MD Anderson Cancer Center, Sarah Cannon, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Churchill Hospital, Novartis (Switzerland)
Language: English

Topic: PI3K/AKT/mTOR signaling in cancer
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: alpelisib, PI3Kα inhibitor, PIK3CA mutation, PI3K/Akt signaling, dose escalation, hyperglycemia, drug safety, pharmacokinetics, oral anticancer drugs, breast cancer, colon cancer, solid tumors, dose-limiting toxicity, PI3K inhibitors
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2070765493
Cites:
Cited by: 65
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security